Teal Health Unveils Landmark Study Results Showing Teal Wand™ Self-Collected Samples Match Clinician Collected Samples

San Francisco, CA – March 18, 2025 – Teal Health, a women’s health company on a mission to eradicate cervical cancer by bringing at-home cervical cancer screening to the US, announced groundbreaking clinical trial results at the Eurogin International Multidisciplinary HPV Conference, revealing that its Teal Wand™ self-collected cervical screening samples perform equivalently to clinician-collected samples. This milestone underscores Teal Health’s mission to revolutionize cervical cancer screening by providing a convenient, at-home solution that aligns with the current gold-standard testing used in clinics.

Teal Health’s at-home cervical cancer screening device received the FDA Breakthrough Device Designation, recognizing both its strong clinical data and importance to public health. The company’s study—the largest nation-wide comparative study in the U.S. with over 600 participants—demonstrated that self-collected sample results matched those of clinician collected samples. Both samples were tested using Roche’s cobas® HPV Test for use on the cobas® 5800/6800/8800 Systems. Leading medical guidelines, including USPSTF and the American Cancer Society (ACS) recognize HPV testing as the most sensitive cervical cancer screening test at 95% sensitivity, which exceeds the traditional Pap smear of 55%.  Pap smears can only be collected by a clinician, whereas HPV samples can be self-collected. 

Key clinical findings from the Teal Health SELF-CERV study include:

• Teal Wand’s clinical sensitivity is 96%, matching the performance of clinician-collected samples, which is also 96%. Clinical sensitivity is the measure of the HPV test’s ability to correctly identify women who have developed cervical cancer or precancer.
• Self-collected sample agreement of 95% with clinician-collected samples, surpassing the threshold for equivalency, set at 87%.
• High usability, with 99% reporting no difficulty, 92% completed collection in under 5 minutes, and 98% of self-collected samples being valid for analysis, demonstrating strong patient understanding and capability to perform the self-collection.

Beyond performance metrics, the study also highlighted a significant preference among women for at-home screening. An overwhelming 94% of participants indicated they would choose Teal Health’s self-collection option if they knew it provided the same accuracy as a clinician-collected sample, and 86% reported they would be more likely to stay up-to-date with routine screening if an at-home option were available. These statistics show the need for diverse screening options. Teal prioritized inclusion in the SELF-CERV study, ensuring clinical trial participants represented the US population across race, ethnicity, gender, income, and geography. 

While current HPV screening methods effectively detect pre-cancer with up to 95% sensitivity, the traditional in-office approach has resulted in nearly one in three women falling behind on their screenings. Unlike other cancer screenings that rebounded after the COVID-19 pandemic, cervical cancer screening rates remain stagnant, with barriers such as appointment availability, time constraints, and discomfort with the speculum exam deterring many women from routine care.

Teal Health’s at-home alternative which couples a telehealth platform with the Teal Wand directly addresses these challenges, offering a comfortable, accessible, and clinically validated alternative that could significantly improve screening participation rates for this nearly 100% preventable disease.

The Eurogin Conference is a prestigious global event convening top scientific minds in HPV detection, prevention, and treatment. By presenting its pivotal SELF-CERV study at this influential forum, Teal Health is contributing to the international conversation on cervical cancer eradication and advocating for expanded access to life-saving screening technologies.

“With these results, we are one step closer to offering US women a scientifically validated, at-home cervical cancer screening option which is currently undergoing rigorous FDA review,”

said Kara Egan, CEO & Co-founder of Teal Health.

“We believe this innovation has the power to transform preventive care, eliminate unnecessary barriers, and ultimately save lives.”

About Teal Health

Teal Health is on a mission to design a better healthcare experience for women – starting with cervical cancer screenings. By creating the option for a woman to screen for cervical cancer from the comfort of home and providing telehealth follow-up, Teal can increase access to this life-saving cancer screening. Teal Health is a member of the Cervical Cancer Roundtable, a joint collaboration between the American Cancer Society and the Biden Cancer Moonshot, a coalition of industry leaders with the goal of eliminating cervical cancer as a public health concern in the US. To learn more, visit www.getteal.com.